title: [Cervical cancer].
abstract: Cervical cancer is the third most common malignancy in women and a major cause of morbidity and mortality particularly in developing countries. In Switzerland cervical cancer is nowadays a relative rare cancer with annually 230 new cases. Decreasing incidence, observed in all age groups, is certainly due to improved primary and secondary prevention such as comprehensive screening programs and in future with vaccination against human papilloma viruses. Improvements in the treatment of cervical cancer led to a reduction of mortality. This review article summarizes the current standard of care with and the available treatment modalities.
authors.affiliation: Klinik für Gynäkologie, UniversitätsSpital Zürich. patrick.imesch@usz.ch
authors.forename: Patrick
authors.initials: P
authors.lastname: Imesch
authors.forename: Daniel
authors.initials: D
authors.lastname: Fink
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008403:Mass Screening; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D011182:Postoperative Care; D015996:Survival Rate; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*; D002578:Uterine Cervical Dysplasia / Q000401:mortality / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*
chemical_list: D053918:Papillomavirus Vaccines